Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer

Miles, D.; Chan, Arlene; Dirix, L.; Cortés, J.; Pivot, X.; Tomczak, P.; Delozier, T.; Sohn, J.; Provencher, L.; Puglisi, F.; Harbeck, N.; Steger, G.; Schneeweiss, A.; Wardley, A.; Chlistalla, A.; Romieu, G.

Access Status

Fulltext not available

Authors

Miles, D.

Chan, Arlene

Dirix, L.

Cortés, J.

Pivot, X.

Tomczak, P.

Delozier, T.

Sohn, J.

Provencher, L.

Puglisi, F.

Harbeck, N.

Steger, G.

Schneeweiss, A.

Wardley, A.

Chlistalla, A.

Romieu, G.

Date

2010

Type

Journal Article

Metadata

Show full item record

Citation

Miles, D. and Chan, A. and Dirix, L. and Cortés, J. and Pivot, X. and Tomczak, P. and Delozier, T. et al. 2010. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. Journal of Clinical Oncology. 28 (20): pp. 3239-3247.

Source Title

Journal of Clinical Oncology